Agios Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Agios Pharmaceuticals's estimated annual revenue is currently $203.2M per year.
- Agios Pharmaceuticals received $617.5M in venture funding in January 2018.
- Agios Pharmaceuticals's estimated revenue per employee is $406,400
- Agios Pharmaceuticals's total funding is $119.8M.
- Agios Pharmaceuticals's current valuation is $1.8B. (January 2022)
Employee Data
- Agios Pharmaceuticals has 500 Employees.
- Agios Pharmaceuticals grew their employee count by 0% last year.
Agios Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, Controller | Reveal Email/Phone |
5 | VP, Data Management & Clinical Systems | Reveal Email/Phone |
6 | Assistant to CEO & Chief People Officer at Agios Pharmaceuticals | Reveal Email/Phone |
7 | VP, Head IT and Facilities | Reveal Email/Phone |
8 | VP, Medical Strategy | Reveal Email/Phone |
9 | Executive Assistant to the Chief Technical Operations Officer & Chief Business Officer | Reveal Email/Phone |
10 | Head Research And Development | Reveal Email/Phone |
Agios Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Agios Pharmaceuticals?
At Agios, we are doing incredibly important and difficult work. We are trying to discover and develop breakthrough medicines, and we have a clear motivator people with cancer and rare genetic diseases who are counting on us to be successful. We are a science-driven research organization. We have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. It takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. Our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. We call this the "other side of possible."
keywords:Biotechnology,Healthcare,Pharmaceuticals
$119.8M
Total Funding
500
Number of Employees
$203.2M
Revenue (est)
0%
Employee Growth %
$1.8B
Valuation
N/A
Accelerator
Agios Pharmaceuticals News
Agios Pharmaceuticals Tibsovo Market Breakdown by Type: 60 Tablets; 30 Tablets. Tibsovo Market breakdown by application:.
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular...
Agios Pharmaceuticals, Inc. In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased...
CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a Treatment CAMBRIDGE, Mass. and ROSTOCK, Germany ...
In biotech, you raise money when you can. And just days after Agios $AGIO spelled out plans for a shot at two accelerated approval plans for its two top drugs, CEO David Schenkein isn’t about to let the opportunity pass. Agios has filed to sell $150 million in shares to cover upcom ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 500 | 58% | N/A |
#2 | $92.1M | 501 | 0% | $127M |
#3 | $7.5M | 503 | 29% | N/A |
#4 | $91.4M | 504 | -4% | N/A |
#5 | $35M | 512 | 6% | N/A |
Agios Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-07-08 | $33.0M | A | Third Rock Ventures, Flagship Ventures | Article |
| 2011-11-18 | $78.0M | C | Celgene | Article |
| 2014-04-24 | $88.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2014-12-11 | $175.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2014-12-12 | $220.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2016-09-15 | $172.5M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2017-04-26 | $250.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2018-01-19 | $400.0M | Undisclosed | Multiple | Article |
| 2018-01-22 | $475.0M | Undisclosed | Multiple | Article |
| 2018-01-25 | $617.5M | Undisclosed | Multiple | Article |